<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381547</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-802</org_study_id>
    <nct_id>NCT03381547</nct_id>
  </id_info>
  <brief_title>A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010</brief_title>
  <acronym>Willow II</acronym>
  <official_title>An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARMO BioSciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of different dose levels and dose formulations of AM0010 in
      healthy adult patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, single dose, 3-way crossover study to evaluate the
      pharmacokinetics of different dose levels and dose formulations of AM0010 in healthy adult
      subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">April 9, 2018</completion_date>
  <primary_completion_date type="Actual">February 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, Cmax</measure>
    <time_frame>43 days</time_frame>
    <description>maximal plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, Tmax</measure>
    <time_frame>43 days</time_frame>
    <description>maximal concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, AUC</measure>
    <time_frame>43 days</time_frame>
    <description>area under the plasma concentration curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, CL/F</measure>
    <time_frame>43 days</time_frame>
    <description>clearance (CL/F).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>43 days</time_frame>
    <description>Incidence of adverse events, injection site reactions, clinically relevant changes in laboratory values, and vital signs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AM0010: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AM0010: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AM0010: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>AM0010 Alone</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 and 55 years of age, inclusive

          2. Must have a body mass index (BMI) between 19 and 32 (kg/m2) at study Screening

          3. Must be HIV negative by HIV 1/0/2 testing

          4. Must be Hepatitis B (HBV) surface antigen negative

          5. Must be Hepatitis C (HCV) antibody negative

          6. Females must have a negative serum pregnancy test

          7. Females of childbearing potential must agree to utilize protocol recommended highly
             effective contraception methods from Screening throughout the duration of study dosing
             and for 30 days following the last dose of study drug.

          8. Must refrain from blood donation from 30 days prior to Day 0 through completion of the
             study and continuing for at least 30 days from date of last dose of study drug

        Exclusion Criteria:

          1. Pregnant or lactating subjects

          2. Have previously participated in an investigational trial involving administration of
             any investigational compound within 30 days prior to the study dosing

          3. Have poor venous access and are unable to donate blood

          4. Have been vaccinated within 90 days of study dosing

          5. Current alcohol or substance abuse judged by the Investigator to interfere with
             subject compliance

          6. Have history of significant drug sensitivity or drug allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

